Tapentadol extended-release as a therapeutic strategy for pain control in cases of osteoarthritis. Case reports
Tapentadol de liberação prolongada como estratégia terapêutica para o controle da dor em casos de osteoartrite. Relato de casos
Frederico Barra de Moraes; André Cicone Liggieri; David Sadigursky
Abstract
BACKGROUND AND OBJECTIVES: Osteoarthritis affects many individuals worldwide and is caused by multiple factors that lead to joint wear and tear, inflammation and, consequently, chronic pain that is difficult to treat. It is predominant in seniors, but not restricted to older age groups. Pain reduction is prioritized when facing crises, so that rehabilitation work and postural corrections can be applied later. The present study aimed to evaluate the analgesic potential of tapentadol extended-release (ER) in three patients with osteoarthritis who had undergone numerous previous treatments and had a history of moderate to severe chronic pain.
CASE REPORTS: Three women, aged 49, 75 and 86 years old, diagnosed with osteoarthritis, with complaints of severe pain and who had undergone numerous therapies including drug use, without significant pain control were included in the study. The use of tapentadol ER was recommended and adjusted to each patient according to the intensity of pain. All of them responded satisfactorily and returned to their daily activities. One of them presented nausea after two days of tapentadol use, which was controlled with an antiemetic drug only during the two days of nausea
CONCLUSION: Tapentadol ER was effective in controlling pain from osteoarthritis in the three cases evaluated, without serious adverse effects. The period and dosage of tapentadol ER must be in accordance with the clinical evolution of each patient.
Keywords
Resumo
JUSTIFICATIVA E OBJETIVOS: A osteoartrite afeta muitos indivíduos em todo o mundo, é causada por múltiplos fatores que conduzem ao desgaste articular, a inflamações e, consequentemente, a dores crônicas de difícil tratamento. É predominante em idosos, mas não restrita às faixas etárias mais elevadas. A diminuição da dor é priorizada diante das crises, para que trabalhos de reabilitação e correções posturais possam ser aplicados posteriormente. O presente estudo teve por objetivo avaliar o potencial analgésico do tapentadol de liberação prolongada (LP) em três pacientes com osteoartrite que já haviam passado por inúmeros tratamentos prévios, com histórico de dor crônica de moderada a intensa.
RELATO DOS CASOS: Três pacientes do sexo feminino, com idades de 49, 75 e 86 anos, diagnosticadas com osteoartrite, com queixas de dor intensa e que haviam passado por inúmeras terapias e uso de fármacos, sem controle significativo da dor. O uso do tapentadol LP foi recomendado e ajustado a cada paciente conforme a intensidade da dor e todas elas apresentaram resposta satisfatória e retomaram suas atividades diárias. Uma delas apresentou náusea após dois dias de uso do fármaco, que foi controlada com um fármaco antiemético somente durante dois dias de enjoo.
CONCLUSÃO: O tapentadol LP foi efetivo para controlar as dores decorrentes da osteoartrite nos três casos avaliados, sem efeitos adversos graves. O período e a dose do tapentadol LP deve considerar a evolução clínica de cada paciente.
Palavras-chave
References
1 Sacitharan PK. Ageing and osteoarthritis. Subcell Biochem. 2019;91:123-59.
2 Xia B, Di Chen, Zhang J, Hu S, Jin H, Tong P. Osteoarthritis pathogenesis: a review of molecular mechanisms. Calcif Tissue Int. 2014;95(6):495-505.
3 Franco-Trepat E, Guillán-Fresco M, Alonso-Pérez A, Jorge-Mora A, Francisco V, Gualillo O, Gómez R. Visfatin connection: present and future in osteoarthritis and osteoporosis. J Clin Med. 2019;8(8):1178.
4 Abramoff B, Caldera FE. Osteoarthritis: pathology, diagnosis, and treatment options. Med Clin North Am. 2020;104(2):293-311.
5 Mahajan A, Patni R. Menopause and Osteoarthritis: Any Association? J Midlife Health. 2018;9(4):171-2.
6 Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;27:393(10182):1745-59.
7 Felson DT, Zhang Y, Hannan MT, Naimark A, Weissman BN, Aliabadi P, Levy D. The incidence and natural history of knee osteoarthritis in the elderly, the framingham osteoarthritis study. Arthritis Rheum. 1995;38(10):1500-5.
8 Coimbra IB, Plaper PG, Campos, GC. Generating evidence and understanding the treatment of osteoarthritis in Brazil: a study through Delphi methodology. Clinics. 2019;74:e722.
9 Hoy SM. Tapentadol extended release: in adults with chronic pain. Drugs. 2012;12;72(3):375-93.
10 Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Raffa RB, Bisney J. Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain. Pain Ther. 2018;7(1):37-57.
11 Mateos RG, Bernal DS, Morera LMT, Ferri CM, Escobar AE. Long-Term Effectiveness and Tolerability of Pain Treatment with Tapentadol Prolonged Release. Pain Physician. 2021;24(1):75-85.
12 Pujol J, Martínez-Vilavella G, Doreste A, Blanco-Hinojo L, Ojeda F, Llorente-Onaindia J, Polino L, Deus J, Monfort J. Tapentadol effects on brain response to pain in sensitized patients with knee osteoarthritis. Rheumatology (Oxford). 2022; 30;61(6):2335-2345.
13 GRUNENTHAL Inc. Palexis LP®. Available in: file:///C:/Users/cinth/Downloads/bula_1681752922475.pdf
14 Zannikos PN, Smit JW, Stahlberg HJ, Wenge B, Hillewaert VM, Etropolski MS. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects. J Opioid Manag. 2013;9(4):291-300.
15 Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lantéri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114(1-2):29-36.
16 Chen L, Yu Y. Exercise and Osteoarthritis. Adv Exp Med Biol. 2020;1228:219-231.
17 Roos EM, Arden NK. Strategies for the prevention of knee osteoarthritis. Nat Rev Rheumatol. 2016;12(2):92-101.
18 Etropolski M, Kuperwasser B, Flügel M, Häufel T, Lange B, Rauschkolb C, Laschewski F. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials. Adv Ther. 2014;31(6):604-20.
19 Biondi DM, Xiang J, Etropolski M, Moskovitz B. Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain. J Opioid Manag. 2015;11(5):393-403.
20 Wild JE, Grond S, Kuperwasser B, Gilbert J, McCann B, Lange B, Steup A, Häufel T, Etropolski MS, Rauschkolb C, Lange R. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010;10(5):416-27.
21 CDC guideline for prescribing opioids for chronic pain. Available in:
Submitted date:
02/26/2023
Accepted date:
09/08/2023
Facebook
Google+
Twitter
LinkedIn
Mendeley
Email